Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.

[1]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[2]  K. Liu,et al.  Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity. , 2010, Bioorganic & medicinal chemistry letters.

[3]  Jinping Gan,et al.  Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. , 2010, Bioorganic & medicinal chemistry letters.

[4]  Bryan L. Roth,et al.  Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment , 2009, Molecular Pharmacology.

[5]  M. Andrews,et al.  Design and synthesis of pyridazinone-based 5-HT(2C) agonists. , 2009, Bioorganic & medicinal chemistry letters.

[6]  David W. Gordon,et al.  Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists. , 2009, Bioorganic & medicinal chemistry letters.

[7]  G. McMurray,et al.  Pharmacological Properties of 2-((R-5-Chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a Novel and Selective α1A-Adrenergic Partial Agonist, in in Vitro and in Vivo Models of Urethral Function , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  P. Brennan,et al.  Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. , 2009, Bioorganic & medicinal chemistry letters.

[9]  P. Fish,et al.  N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. , 2009, Bioorganic & medicinal chemistry letters.

[10]  Sung Jin Cho,et al.  Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action. , 2009, Journal of medicinal chemistry.

[11]  A. Brown,et al.  7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization. , 2009, Bioorganic & medicinal chemistry letters.

[12]  J. Bauman,et al.  Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists. , 2009, Bioorganic & medicinal chemistry letters.

[13]  C. Anderson,et al.  Lorcaserin (APD356), a Selective 5‐HT2C Agonist, Reduces Body Weight in Obese Men and Women , 2009, Obesity.

[14]  Y. Mbaki,et al.  Investigation of the role of 5‐HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat , 2008, British journal of pharmacology.

[15]  K. Miller,et al.  Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. , 2008, Current opinion in drug discovery & development.

[16]  Brian M. Smith,et al.  Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  S. Tsukamoto,et al.  Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. , 2008, Bioorganic & medicinal chemistry.

[18]  S. Tsukamoto,et al.  Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists. , 2008, Bioorganic & medicinal chemistry.

[19]  J. C. Winter,et al.  Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents , 2008, Pharmacology Biochemistry and Behavior.

[20]  Brian M. Smith,et al.  Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. , 2008, Journal of medicinal chemistry.

[21]  K. Marquis,et al.  5-HT2C receptor agonists as an innovative approach for psychiatric disorders. , 2007, Drug news & perspectives.

[22]  C. Villalón,et al.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  A. Kalgutkar,et al.  Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation , 2007, Drug Metabolism And Disposition.

[24]  P. Seymour,et al.  CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity , 2007, Neuropharmacology.

[25]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[26]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[27]  N. Barnes,et al.  Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists , 2006 .

[28]  E. Lacivita,et al.  Selective agents for serotonin2C (5-HT2C) receptor. , 2006, Current topics in medicinal chemistry.

[29]  B. Nilsson.  5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. , 2006, Journal of medicinal chemistry.

[30]  Brian M. Smith,et al.  The potential use of selective 5-HT2C agonists in treating obesity , 2006, Expert Opinion on Investigational Drugs.

[31]  J. Sikorski.  Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. , 2006, Journal of medicinal chemistry.

[32]  M. J. Bishop,et al.  New 5-HT2C receptor agonists , 2003 .

[33]  D. Harmer,et al.  5‐HT2B receptors play a key role in mediating the excitatory effects of 5‐HT in human colon in vitro , 2002, British journal of pharmacology.

[34]  A. Mai,et al.  Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. , 1997, Journal of medicinal chemistry.

[35]  T. Blackburn,et al.  Further characterization of 5‐hydroxytryptamine receptors (putative 5‐HT2B) in rat stomach fundus longitudinal muscle , 1994, British Journal of Pharmacology.

[36]  J. Barrish.  Accounts in drug discovery : case studies in medicinal chemistry , 2011 .

[37]  T. Maurer,et al.  Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. , 2010, Bioorganic & medicinal chemistry letters.

[38]  G. Kennett,et al.  5-HT2C ligands: recent progress. , 2008, Progress in medicinal chemistry.

[39]  Seiki Yamaguchi,et al.  Studies of Seven-membered Heterocyclic Compounds Containing Nitrogen. IX. The Synthesis of 5-Ethoxycarbonyl-1-azacycloheptan-4-one and Its Derivatives , 1968 .